Every letter we have printed

What is not studied at all is what happens when somebody maintains for years and then has to stop for reasons outside their control. Every account of stopping in the literature is a planned stop, and planned stops are the minority case here.

Your series has not yet addressed what a buyer should do with a single blind result that disagrees with a supplier’s certificate. The honest answer is very little, and saying so would be more useful than another round of methodological argument.

A modest proposal: publish the shipping cost alongside the result. It sounds irrelevant and it is the fastest way for a reader to tell a genuine retail purchase from a sample that arrived by arrangement.

Sellers who cannot obtain a badge sometimes make their own. I have three in my collection that imitate a service’s house style closely enough to pass a glance and carry no link at all. The genuine mark has created a market for its own imitation.

There is an argument that the badge is aimed at the seller rather than the buyer: it exists so that suppliers who test can distinguish themselves from those who do not. If that is the purpose, it is a poor consumer instrument being asked to do a trade-signalling job.

The buyer-submitted result and the seller-submitted result are not the same evidence and should not be printed in the same column. Your tables do distinguish them, which I appreciate; most listings do not, and a reader comparing across sources is comparing two different experiments.

Mass loss of any origin is associated with density change in the older literature, which makes the untreated comparator essential and frequently absent. Without it the question of attribution cannot be approached at all.

Areal density is confounded by body size, which is precisely what is changing. That is a real limitation of the standard measurement in exactly this population, and the volumetric alternatives are not widely available.

You write that no trial has measured strength. There are observational cohorts with grip strength data. Why do you insist on randomised measurement?

Bioimpedance estimates total body water and infers the rest, which means that during rapid change it is estimating the quantity that is moving fastest and is least stable. Its precision is fine and its accuracy is a different matter, and the two get conflated constantly.

Thank you for this. It answered the question I came with and raised two I had not thought to ask.

The hindbrain and hypothalamic sites are where the appetite effect lives, and the peripheral vagal contribution is more contested than a general reader would guess from most summaries. Your account distinguishes the two, which matters because they predict different things about tolerance.

Renal expression and the natriuretic findings deserve a paragraph, given how much interest there now is in kidney outcomes. It is a genuinely separate line of work from the metabolic one and it is developing quickly.

Internalisation and recycling determine what a sustained exposure does over days, and almost all the published potency work is measured over minutes. The two timescales answer different questions and the shorter one is the one everybody quotes.

Refrigerator temperature is assumed and rarely verified. Domestic units cycle over a wider band than people expect, and door shelves in particular spend a good deal of time well above the nominal figure.

Agitation matters. A vial carried in a bag for a day has experienced mechanical stress that a vial on a shelf has not, and interfacial stress is a recognised cause of aggregation in protein preparations generally.

Receptor distribution maps come largely from tissue studies with antibodies of variable specificity, and several widely reproduced maps rest on reagents that were later questioned. The provenance of a distribution map matters as much as its content.

Access to a tissue is as important as the presence of a receptor in it, and molecules of this size do not cross every barrier freely. A receptor that cannot be reached is not part of the mechanism.

Your table lists orforglipron with a half-life of 29 to 49 hours. That is a wide range to report as a single figure. What accounts for it?

Half-maximal values from different assay formats can differ by an order of magnitude for the same ligand, which makes any table without the assay method close to decorative.

The structural work on this receptor is now good enough to explain several of the selectivity differences that used to be empirical observations. It is a genuine advance and it has not reached the popular accounts at all.

Timing of the final scan relative to the last dose varies between studies and is not always reported. Fluid shifts on that timescale are large enough to matter for a lean-mass measurement.

The substudies are the most expensive part of these programmes per participant, which is why they are small, and their size is then treated as a weakness of the finding rather than a consequence of the method.

An honest presentation would give the ratio with its confidence interval and the sample size in the same sentence. Three numbers instead of one, and the impression created would be entirely different.

Absorptiometry divides tissue into three compartments and calls one of them lean, which includes water, organ and connective tissue as well as muscle. A fall in lean mass is not the same finding as a fall in muscle, and the reporting almost always translates one into the other.

The reasons literature would improve enormously if a single study published the free-text answers alongside the coded ones. The coding is where the information is lost, and the raw text usually still exists.

The reasons people give at the time and the reasons they give a year later are not the same. Retrospective accounts are tidier and more causal, and any dataset assembled after the fact should be read with that in mind.

Composition of regained tissue is barely studied and is the question I would most like answered. Whether what returns resembles what was lost has practical consequences and there is very little data on it.

Supply interruption is the underdiscussed maintenance risk. A plan that depends on continuous availability of a specific product is a plan with an external dependency, and the last two years have shown how that dependency behaves under stress.

Comparison shopping in this market is conducted on price and purity, in that order, and both are single numbers. A market that compares on two scalars will not develop a third.

Price competition selects against anything that adds cost without being visible to the buyer at the point of decision. Everything discussed in this piece falls into that category, which is why none of it is offered.

Your list of what you asked suppliers for is the right list and I would add one item: the environmental monitoring trend rather than a single result. A trend shows whether a suite is under control; one plate shows what happened on one day.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

A certificate should say what the sample was when it arrived at the laboratory. Powder, solution, sealed vial, decanted aliquot: each supports a different conclusion, and the analytical section is silent on all of them. The best documents in my file open with a description of the container.

Every certificate I hold has a header with a company name and no company address. It is a small thing until you need to write to somebody, at which point the document has told you who did the work and given you no means of reaching them.

The phrase dose-limiting has a precise meaning in trial design and a loose one everywhere else. In a protocol it names the point at which escalation stops; in general use it names discomfort. The two are frequently conflated in coverage of the same study.

Nobody publishes the distribution, only the proportion. Whether effects are mild across most of a population or severe in a small part of it is the question a reader has, and an incidence figure cannot answer it either way.

A point about the exposure profile rather than the receptor. Peak-to-trough variation differs substantially between compounds in this class, and a mechanism driven by peak exposure will present differently from one driven by average exposure. The literature rarely separates the two.

Diode-array spectra are the single most under-used piece of data in this trade. The instrument collects them whether or not anybody looks, and the file is already on the disk. Asking a laboratory to include a spectral homogeneity check costs an analyst five minutes and answers a question the percentage cannot.

A note on detector linearity, which the article passes over. Above a certain injected mass the response stops being proportional, and the main peak reaches that ceiling long before the impurities do. An overloaded injection therefore flatters the impurities rather than the product, which is the opposite of what most readers assume.